Harrow Partners with GoodRx to Enhance Affordable Eyecare Access and Medication Savings

Harrow's Commitment to Affordable Eyecare: A New Initiative with GoodRx

Harrow, a leading North American eyecare pharmaceutical company, embarks on a transformative initiative to enhance the affordability and accessibility of its ophthalmic products. This week, the company launches its Access and Affordability Program, which implements targeted price reductions on key medications such as VIGAMOX® and MAXIDEX®. By reducing costs, Harrow aims to dismantle the financial barriers that often prevent patients from obtaining essential eyecare medications. The initiative not only promises to improve patient outcomes but also reflects the company's commitment to prioritizing patient health and quality of life.

In conjunction with this program, Harrow establishes a strategic partnership with GoodRx, the foremost prescription savings platform in the United States. This collaboration allows patients to access discounts on select products, including FLAREX®, ILEVRO®, and VIGAMOX®, providing a valuable cash-pay option for those who do not have adequate insurance coverage. The partnership is designed to ensure that patients can obtain necessary medications without facing prohibitive costs. By facilitating access through the GoodRx website and mobile app, Harrow and GoodRx work together to streamline the procurement process for patients, making it easier for them to manage their eyecare needs effectively.

Mark L. Baum, Harrow’s Chairman and CEO, underscores the initiative's alignment with the company's founding mission of helping patients preserve their sight. He acknowledges the financial strain that high insurance co-payments can impose on patients and believes that the new pricing strategy coupled with GoodRx's platform creates a win-win scenario for both patients and shareholders. Through these combined efforts, Harrow is not only expanding its reach but also reinforcing its commitment to supporting eyecare professionals and ensuring that millions of patients can access sight-saving treatments when they need them most.

In addition to the Access and Affordability Program, Harrow continues to focus on the discovery and development of innovative ophthalmic products. The company is dedicated to addressing the challenges that patients face in accessing necessary medications, ensuring that its portfolio remains both available and affordable. As the eyecare landscape evolves, Harrow's initiatives play a crucial role in enhancing patient care and outcomes within the industry.

Through these recent developments, Harrow strengthens its position as a leader in affordable eyecare, demonstrating a proactive approach to the pressing issue of medication accessibility. By partnering with GoodRx and implementing meaningful price reductions, the company not only addresses immediate concerns but also sets a precedent for future initiatives aimed at improving the lives of patients reliant on eyecare solutions.